
Oncology Fellow | Massachusetts General Hospital/DFCI | @MassGenBrigham | #Melanoma | #Immunotherapy
Pittsburgh, PA
Joined September 2022
- Tweets133
- Following419
- Followers313
- Likes1K
Andy Knight retweeted
BREAKING: The most controversial article of the year, claiming that early morning immunotherapy works better than in the afternoon, is now retracted.
After reading the responses provided by the authors to the inconsistencies raised in the web, the @NatureMedicine editors no longer have confidence in the integrity of the results. The only prospective evidence that time-of-day matters for immunotherapy is now gone.
nature.com/articles/s41591-0…
To me, this means (at least) two things.
First, it confirms that prudence on this topic was and remains critical. For as inexpensive it may be to give a drug earlier or later in the day, it carries a much more relevant cost: the one of scientific integrity. We owe our patients to make decisions based on solid data. We should not give up this practice too easily, particularly in the presence of several concerning red flags.
Second, this retraction should also prompt a broader reflection on the current state of peer review, in which unpaid reviewers struggle to keep up with a steady rise in submitted papers. Journals need to improve the process by implementing a formal, consistent, in-depth review of each paper by paid professionals. A practice that, in this case, may have avoided a retraction arriving after 22 citations and after inclusion of this study in at least one meta-analysis. And possibly, after some physicians had already changed their practice in IO administration.
For a thoughtful recap of this story, I recommend this well-written new piece in @ScienceMagazine by Laura Agudelo. I’m grateful to Laura for including my perspective in the article.
science.org/content/article/…
What are the key issues that have emerged on the @NatureMedicine time-of-day IO paper?
1. The clinical trial protocol uploaded to Nature was v1 dated Jan 2, 2022; however, the protocol includes references published in 2024. This calls into question when the protocol was written and if/when it was amended.
2. The clinicaltrials.gov record is concerning and calls into question whether the study was actually randomized.
a. In the first record 9/2022, although the study was noted as randomized, the inclusion/exclusion criteria read as though it was a retrospective study, e.g., “First-line patients received immunological monotherapy or immunological combined chemotherapy” as an inclusion criteria and “Lack of clinical diagnosis and treatment information or loss of follow-up” as an exclusion criteria.
b. In the first record, the primary endpoint, sample size, treatment and ECOG criteria do not match what was in the protocol dated Jan 2, 2022.
c. On 3/19/2024, the study was changed from randomized/interventional to an observational case-control study
d. It was not until 3/30/2024 (2 months before end of randomization) that the study was changed to the design described in the manuscript.
3. The OS K-M curve presented at ASCO had errors – i.e., the censor marks do not match the at-risk table. This raises concerns about the integrity of statistical analyses.
4. The shape of the PFS does not match expectations. With a 6-week scan schedule, one would expect a stair-step drop every 6 weeks when patients have their scheduled imaging. Their PFS curve does not – it is smooth. Of note, in an observational study, a PFS curve generally does not have a staircase look because scans are not performed on a regular set schedule.
5. The 95% CI for the lower bound of the median OS in the manuscript is NE. This is not possible as the median was estimated. There are inconsistencies in the p-values in Table 1 (Baseline Characteristics)
Credit to Daniel Brickman, Amanda Nottke and David Swank for creating this list — and to @houndcl for first identifying several of these issues.
Andy Knight retweeted
3 new #NatureMedicine trials show FMT can boost ICI activity across tumors:
• TACITO – mRCC PFS benefit
• PERFORM – encapsulated FMT + ICI feasibility
• FMT-LUMINate – ORR 80% NSCLC, 75% melanoma
Microbiome engineering is entering oncology (rdcu.be/e7ALT).
Andy Knight retweeted
Excellent presentation by @MeghanMooradian from
@DFCI presenting @UPMCHillmanCC led Neo-Mel-T trial evaluating neoadjuvant anti-TIM-3+anti-PD-1 vs. neoadjuvant anti-PD-1 in high-risk resectable #melanoma. MPR 56%, 1-year RFS 87% with no surgical delays, 15%TRAE with dostar/cobo
Andy Knight retweeted
Extremely excited re: IMA203 - PRAME TCR T cells Ph 1 study published in @NatureMedicine! This is a transformative Rx in #melanoma for HLA-A201+ & PD1 refractory pts. Compared to TIL, easier to make, less toxic & so far ~2x response rate in heavily pre-Rx.
nature.com/articles/s41591-0…
Andy Knight retweeted
Jeffrey S Weber's life is a testament to mentorship, patient care, sacrifice, leadership. Thank you @jitcancer for allowing us to share a glimpse of this giant.
jitc.bmj.com/content/12/9/e0…
@jasonlukemd @BernardAFox @MoffittNews @uscnorris @nyulangone @theNCI @ASCO @CureMelanoma @MelanomaReAlli
Andy Knight retweeted
We lost a legend today. Jeff meant so much to the fields of melanoma and immuno-oncology. We were fortunate to learn from him and share the fruits of his labor with our patients. May his memory be a blessing.
So sad to hear about the passing of Jeff Weber, a giant in the field of oncology. He was involved in the early days of cytokine and cell therapy and most recently led studies of personalized vaccines for melanoma patients. I originally worked with Jeff @theNCI over 30 years ago. He was a great friend and colleague to many of us in the melanoma and immunotherapy field and we will remember him as a pioneer, thought leader and compassionate physician.
@sitcancer @DrJamesMule @BernardAFox
Andy Knight retweeted
Excited to share our paper out today in @CellCellPress with @BcellBruno @Vignali_Lab! Part of a trio of papers, we show in #Melanoma, anti-PD1+anti-LAG3 therapy modifies CD8 differentiation to promote enhanced effector function tinyurl.com/2ap5w9va
Andy Knight retweeted
Had a great time at #ASCO24 this year! Thank you to my wonderful mentors @AndyKnightMD and @jmkirkwood for the support and guidance with my project. And thank you to everyone who stopped by my poster. #Melanoma #Immunotherapy
Andy Knight retweeted
Nice review here on recent advancements for #melanoma developmental #immunotherapy. Great work @AndyKnightMD! Useful read as prep during your travels to #ASCO24. Bispecifics, vaccines, oncolytic virus, adoptive cell transfer, cytokines & more!
rdcu.be/dI04a
Andy Knight retweeted
This is the face of very proud @PittIMChiefs @AndyKnightMD, @CaseySkittle, @valenjaramillo7 and PD @ACarterMD after witnessing the hard work and dedication of each one of our residents!
We couldn’t be more honored to be here and watch all of you grow 💜 @PittGIM @PittDeptofMed
Andy Knight retweeted
Outgoing and incoming @PittIMChiefs chief residents at #AIMW24!! So proud of these amazing humans. @PittGIM @PittDeptofMed
Andy Knight retweeted
"My research aims to uncover any differences in treatment outcomes among patients with pre-existing type II diabetes at the time of their metastatic melanoma diagnosis. Discovering such differences could prompt further investigation, potentially influencing recommendations regarding dosage and follow-up intervals tailored specifically for this patient population."
This #MRFResearchWednesday, Read about 2024 Medical student grant recipient @SabrinaBruno_ from @PittHealthSci and her research on Outcomes and immune profile of type II diabetic patients on nivolumab. to learn more about Sabrina's research - buff.ly/44b3g1m
Andy Knight retweeted
Published in @JCO_ASCO, Dr. Jason Luke (@jasonlukemd) shares a three year update for the KEYNOTE-716 study. These results continue to support the use of pembrolizumab adjuvant therapy in patients with resected stage IIB or IIC melanoma. ascopubs.org/doi/10.1200/JCO…
Andy Knight retweeted
Thanks, @DrChoueiri; and to the patients & study team, @eaonc @SWOG @ALLIANCE_org @montypal @neerajaiims @BrianCostelloMD Amie Kim, Naomi Haas, Mike Carducci, Wayne Harris @LynneWagnerPhD David Cella, Chris Ryan @JCO_ASCO @UPMCHillmanCC
Important study and an unmet medical need in kidney cancer (M1NED)—
Congrats @LenAppleman @eaonc and the whole team on this publication in @JCO_ASCO!
@OncoAlert @ASCO @kidneycan @KidneyCancer
Andy Knight retweeted
Lifileucel (TIL cell therapy from @IovanceBio) is now FDA approved for advanced PD-1 refractory melanoma!!! The melanoma community is so grateful to the patients, caregivers, and clinicians who have made the clinical trials of this therapy possible and got lifileucel to approval. We are very excited to bring this life-saving therapy to patients ASAP! Available immediately at @StanfordCancer!!!
ir.iovance.com/news-releases…
Andy Knight retweeted
Excited to have our abstract accepted for presentation at the upcoming #DDW2024. Thanks to my mentor @eaks790 for the support and encouragement. @BrighamGI @DDWMeeting 🥳 – at Brookline, MA
Andy Knight retweeted
Another successful Medicine Grand Rounds on the books. You all make us proud and it is an absolute pleasure to witness each one of your achievements. We left today knowing more about different topics in cardiology, oncology and GI, but also left INSPIRED BY YOU.
Thank you! 💜
Andy Knight retweeted
🗓️ Join us at noon on Tuesday, 12.12.23, for the next DOM Grand Rounds!
Tuesday's MGR will feature research presentations from our internal medicine residents.
For the link, visit dom.pitt.edu/grandrounds/.
Andy Knight retweeted
To all of our residents/recent grads that recently match to different fellowships, CONGRATULATIONS!!! We are proud and excited to see you achieve all your goals and dreams here @UPMC 💜 or wherever else you are going for this next chapter of your lives.
#Lifechangingresidency
Andy Knight retweeted
So happy! My partner @AndyKnightMD matched his top choice today! @DanaFarber hem onc fellowship is getting the best! 🤩🥹 no more long distance 🙌🏼 #matchday #fellowshipmatch #hemoncfellowship






































